Pair Name | Halofuginone, Cisplatin | ||
Phytochemical Name | Halofuginone (PubChem CID: 400772 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Halofuginone, Cisplatin | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | PSMD9 | hsa5715 | |
Down-regulation | Phosphorylation | RB1 | hsa5925 | |
In Vitro Model | NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 |
NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 | |
Result | Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways |
No. | Title | Href |
---|---|---|
1 | Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways. Front Cell Dev Biol. 2021 Nov 24;9:773048. doi: 10.3389/fcell.2021.773048. | Click |